Interplay of Microbiome and Ulcerative Colitis

Gowthami Reddy Mareddy

doi:10.55006/biolsciences.2022.2403

Authors

Gowthami Reddy Mareddy JSS Academy of Higher Education and Research, Mysuru, India. https://orcid.org/0000-0003-3183-3200

DOI:

https://doi.org/10.55006/biolsciences.2022.2403

Keywords:

Microbiome, Ulcerative colitis, Inflammatory bowel disease, Dysbiosis

Abstract

The gut microbiome plays a crucial role in the pathogenesis of ulcerative colitis (UC), a chronic inflammatory bowel disease. Dysbiosis, characterized by reduced microbial diversity and shifts in bacterial populations, is commonly observed in UC patients. Key microbial species such as Firmicutes, Bacteroidetes, and Proteobacteria are implicated in disease development, influencing immune responses and intestinal barrier integrity. This review explores the complex interplay between the microbiome and UC, focusing on mechanisms such as immune modulation, barrier disruption, and the production of metabolites like short-chain fatty acids. Microbiome-targeted therapies, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary interventions, show promise in restoring microbial balance and alleviating UC symptoms. Additionally, emerging microbiome-modulating drugs provide new therapeutic avenues. Despite these advancements, challenges remain, including the heterogeneity of UC, the need for personalized treatments, and the causal relationship between microbiome changes and UC. Future research should focus on longitudinal studies, personalized therapies, and the application of advanced technologies like metagenomics to deepen our understanding of the microbiome’s role in UC. Long-term clinical trials will be essential for determining the safety and efficacy of microbiome-based treatments. This review highlights the potential of the microbiome as a therapeutic target and underscores the need for continued research to improve UC management.

Downloads

Download data is not yet available.

References

1. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, et al. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14.

2. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55(2):205–11.

3. Wu H-J, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012;3(1):4–14.

4. Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017;11(4):841–52.

5. Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn’s disease. Nat Rev Dis Prim. 2020;6(1):22.

6. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013;6(4):295–308.

7. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science (80- ). 2011;334(6052):105–8.

8. Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64.

9. Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol. 2015;13:105–20.

10. Baumgart D, Baumgart DC. Crohn’s disease and ulcerative colitis. Springer; 2017.

11. Parvez S, Malik KA, Ah Kang S, Kim H. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol. 2006;100(6):1171–85.

12. Macia L, Tan J, Vieira AT, Leach K, Stanley D, Luong S, et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun. 2015;6(1):6734.

13. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–41.

14. García-Montero C, Fraile-Martínez O, Gómez-Lahoz AM, Pekarek L, Castellanos AJ, Noguerales-Fraguas F, et al. Nutritional components in Western diet versus Mediterranean diet at the gut microbiota–immune system interplay. Implications for health and disease. Nutrients. 2021;13(2):699.

15. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science (80- ). 2016;352(6285):544–5.

16. Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho K-L, Kronman MP, et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. Off J Am Coll Gastroenterol ACG. 2014;109(11):1728–38.

17. Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci. 2007;104(34):13780–5.

18. Zuo T, Kamm MA, Colombel J-F, Ng SC. Urbanization and the gut microbiota in health and inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):440–52.

19. Gao X, Cao Q, Cheng Y, Zhao D, Wang Z, Yang H, et al. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc Natl Acad Sci. 2018;115(13):E2960–9.

20. Lopez-Siles M, Martinez-Medina M, Busquets D, Sabat-Mir M, Duncan SH, Flint HJ, et al. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. Int J Med Microbiol. 2014;304(3–4):464–75.

21. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci. 2008;105(43):16731–6.

22. Maldonado‐Arriaga B, Sandoval‐Jiménez S, Rodríguez‐Silverio J, Lizeth Alcaráz‐Estrada S, Cortés‐Espinosa T, Pérez‐Cabeza de Vaca R, et al. Gut dysbiosis and clinical phases of pancolitis in patients with ulcerative colitis. Microbiologyopen. 2021;10(2):e1181.

23. De Cruz P, Kang S, Wagner J, Buckley M, Sim WH, Prideaux L, et al. Association between specific mucosa‐associated microbiota in Crohn’s disease at the time of resection and subsequent disease recurrence: A pilot study. J Gastroenterol Hepatol. 2015;30(2):268–78.

24. Caenepeel C, Sadat Seyed Tabib N, Vieira‐Silva S, Vermeire S. how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(9):1453–68.

25. Zhu S, Han M, Liu S, Fan L, Shi H, Li P. Composition and diverse differences of intestinal microbiota in ulcerative colitis patients. Front Cell Infect Microbiol. 2022;12:953962.

26. Macia L, Thorburn AN, Binge LC, Marino E, Rogers KE, Maslowski KM, et al. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev. 2012;245(1):164–76.

27. Boland BS, He Z, Tsai MS, Olvera JG, Omilusik KD, Duong HG, et al. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020;5(50):eabb4432.

28. McGuckin MA, Eri R, Simms LA, Florin THJ, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009;15(1):100–13.

29. Popov J, Caputi V, Nandeesha N, Rodriguez DA, Pai N. Microbiota-immune interactions in ulcerative colitis and colitis associated cancer and emerging microbiota-based therapies. Int J Mol Sci. 2021;22(21):11365.

30. Tian C, Huang Y, Wu X, Xu C, Bu H, Wang H. The Efficacy and Safety of Mesalamine and Probiotics in Mild‐to‐Moderate Ulcerative Colitis: A Systematic Review and Meta‐Analysis. Evidence‐Based Complement Altern Med. 2020;2020(1):6923609.

31. Losurdo G, Iannone A, Contaldo A, Ierardi E, Di Leo A, Principi M. Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis. J Gastrointestin Liver Dis. 2015;24(4):499–505.

32. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients. 2013;5(4):1417–35.

33. Yamashita S, Morine Y, Imura S, Ikemoto T, Saito Y, Takasu C, et al. A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2. World J Surg Oncol. 2021;19(1):142.

34. Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–5.

35. Whelan K, Martin LD, Staudacher HM, Lomer M. The low FODMAP diet in the management of irritable bowel syndrome: an evidence‐based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet. 2018;31(2):239–55.

36. Pu D, Zhang Z, Feng B. Alterations and potential applications of gut microbiota in biological therapy for inflammatory bowel diseases. Front Pharmacol. 2022;13:906419.

37. Zhang M, Zhou Q, Dorfman RG, Huang X, Fan T, Zhang H, et al. Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats. BMC Gastroenterol. 2016;16:1–9.

38. Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145(1):16–27.

39. Tungland B. Human microbiota in health and disease: From pathogenesis to therapy. 2018;

40. Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology. DNA Res. 2009;16(1):1–12.

41. Jaeger N, Gamini R, Cella M, Schettini JL, Bugatti M, Zhao S, et al. Single-cell analyses of Crohn’s disease tissues reveal intestinal intraepithelial T cells heterogeneity and altered subset distributions. Nat Commun. 2021;12(1):1921.

42. Sanders DJ, Inniss S, Sebepos-Rogers G, Rahman FZ, Smith AM. The role of the microbiome in gastrointestinal inflammation. Biosci Rep. 2021;41(6):BSR20203850.